Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

Delayed Quote. Delayed  - 08/26 09:59:55 pm
1.72 USD   -1.15%
08/25 PLURISTEM THERA : PSTI) Secures $8 Million EU Grant for Critical Lim..
08/22 PLURISTEM THERA : Phase III Cell Therapy Company Pluristem Gets $8 M..
08/12 PLURISTEM THERA : Phase III Critical Limb Ischemia Study Wins $8 Mil..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/22/2016 08/23/2016 08/24/2016 08/25/2016 08/26/2016 Date
1.67(c) 1.68(c) 1.69(c) 1.74(c) 1.72(c) Last
226 517 166 122 174 446 144 343 123 225 Volume
-3.47% +0.60% +0.60% +2.96% -1.15% Change
More quotes
Financials ($)
Sales 2016 2,85 M
EBIT 2016 -24,3 M
Net income 2016 -23,6 M
Debt 2016 -
Yield 2016 -
Sales 2017 0,81 M
EBIT 2017 -29,3 M
Net income 2017 -27,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 49,0x
Capi. / Sales2017 173x
Capitalization 139 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
08/25 PLURISTEM THERAPEUTICS : PSTI) Secures $8 Million EU Grant for Critical Limb Isc..
08/22 PLURISTEM THERAPEUTICS : Phase III Cell Therapy Company Pluristem Gets $8 Millio..
08/12 PLURISTEM THERAPEUTICS : Phase III Critical Limb Ischemia Study Wins $8 Million ..
08/09 Pluristem’s Phase III Critical Limb Ischemia Study Wins $8 Million Gran..
08/03 PLURISTEM THERAPEUTICS : Deploys Medidatas Cloud Technology
08/03 PLURISTEM THERAPEUTICS : Advances Towards Multinational Phase III Trial of PLX-P..
08/02 Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Tria..
07/28 PLURISTEM THERAPEUTICS : Advances Towards Multinational Phase III Trial of PLX-P..
07/28 PLURISTEM THERAPEUTICS : advances towards multinational Phase III trial of PLX-P..
07/27 Pluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improv..
More news
Sector news : Biotechnology & Medical Research - NEC
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/02 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
06/22 Midday Gainers / Losers
06/22 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/22 PREMARKET GAINERS / LOSERS AS OF 9 : 15 am
06/22 Pluristem's PLX-PAD cells shows positive effect in animal model of muscular d..
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,17 $
Spread / Average Target 139%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Zami Aberman Chairman & Chief Executive Officer
Yaky Yanay President, COO, CFO, Secretary & Director
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Mark S. Germain Director
Nachum Rosman Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS..53.98%135
INCYTE CORPORATION-26.14%15 499
CELLTRION, INC.--.--%11 596
LONZA GROUP AG14.78%10 334
QUINTILES TRANSNATIONA..10.22%8 935
ALKERMES PLC-44.36%6 737
More Results